scholarly journals Evaluation of hydrated extract of phaseolus Vulgaris L. (bean plant) on hypoglycemia and hypolipidemic in streptozotocin-induced diabetic albino Wistar rats

2019 ◽  
Vol 10 (4) ◽  
pp. 3704-3710
Author(s):  
Helisha Ruth Obonyo ◽  
Senthemarai Selvi V
Keyword(s):  
Phaseolus Vulgaris ◽  
Blood Serum ◽  
Common Bean ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Diabetic Rats ◽  
Low Density ◽  
Phaseolus Vulgaris L ◽  
Reference Drug ◽  
The Impact

The current research was intended to comprehend hypoglycemic and anti-lipidaemic exercises of hydrated common bean (phaseolus Vulgaris L.) seed extracts on streptozotocin-induced diabetic albino rats. At a set portion fluctuate of 100, 200,300 mg/kg body weight of common bean extracts was orally directed as one portion for every day to polygenic disorder rats for a measure of thirty days. The impact of P.vulgaris L. on hypoglycemic, glycosylated hemoprotein (HbA1c) and blood serum lipid profile (Total cholesterin), Triglyceride (TG), very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), High-density lipoprotein (HDL)) in plasma were estimated in the regular and diabetic induced rat. The outcomes demonstrated that quick glucose,serum TC, TG, LDL, VLDL, levels were significantly (p<0.05) attenuate, while blood serum HDL, the level was extensively (p<0.05) upgraded inside the diabetic rats. The inconclusive amount of pace of 300 mg/kg is more reasonable than that of a hundred mg/kg. Our examination so shows that Phaseolus vulgaris L has a powerful adversary to diabetic and anti-lipidaemic impacts on streptozotocin-induced diabetic rats, and results were comparable to reference drug glibenclamide.

scholarly journals PENGARUH FRAKSINASI BUNCIS (PHASEOLUS VULGARIS L.) TERHADAP PENURUNAN KADAR KOLESTEROL TIKUS PUTIH (RATTUS NORVEGICUS L.) YANG HIPERKOLESTEROLEMIA

2020 ◽  
Vol 5 (1) ◽  
pp. 14-20
Author(s):  
Lilik Sulastri ◽  
◽  
Putri Syafalia ◽  
Achmad Fauzi Isa
Keyword(s):  
Phaseolus Vulgaris ◽  
Rattus Norvegicus ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Sprague Dawley ◽  
Phaseolus Vulgaris L

Hiperlipidemia merupakan suatu keadaan meningkatnya kadar lipid darah yang ditandai dengan meningkatnya kadar kolesterol total, Low Density Lipoprotein (LDL), dan trigliserida dalam darah yang melebihi batas normal. Sampai saat ini telah banyak obat yang digunakan untuk penanganan hiperlipidemia baik obat sintetik dan obat herbal. Salah satu obat herbal yang telah digunakan oleh masyarakat Indonesia adalah buncis (Phaseolus vulgaris L.). Tujuan penelitian ini adalah untuk mengetahui pengaruh beberapa ekstrak (n-heksan, etilasetat dan air) buah buncis terhadap penurunan kadar kolesterol tikus jantan galur Sprague Dawley yang telah diinduksi kuning telur puyuh, PTU 0,02% dan asupan pakan aterogenik selama 14 hari. Pengukuran kadar kolesterol dilakukan secara enzimatis dengan alat kolesterolmeter Easy Touch®. Hasil fraksinasi ekstrak etanol buncis dengan pelarut n-heksan, etil asetat, dan air diujikan selama 7 hari dengan dosis 50 mg/kg BB diperoleh fraksi air sebagai fraksi yang paling aktif menurunkan kadar kolesterol darah. Pada uji lanjutan fraksi air dilakukan terhadap 5 kelompok perlakuan (5x5 ekor), yaitu kelompok 1 (Na CMC 0,5%) sebagai kontrol negatif, kelompok 2 (simvastatin 0,18 mg/200 g BB) sebagai kontrol positif dan variasi dosis fraksi air 50 mg/kg BB, 100 mg/kg BB serta 150 mg/kg BB (kelompok 3, 4, dan 5). Selama 21 hari perlakuan tikus tetap diberikan pakan aterogenik dan pengukuran kadar kolesterol dilakukan pada hari ke 0, 14, 21, 28, dan 35. Hasil uji lanjutan menunjukkan bahwa fraksi air ekstrak buncis pada dosis 50 dan 100 mg/kg BB tidak memiliki perbedaan yang nyata dengan simvastatin, sedangkan pada dosis 150 mg/kg BB menunjukkan perbedaan yang nyata dangan simvastatin dalam menurunkan kadar kolesterol.

scholarly journals Regulation of very-low-density-lipoprotein lipid secretion in hepatocyte cultures derived from diabetic animals

1989 ◽  
Vol 262 (1) ◽  
pp. 313-319 ◽  
Author(s):  
J M Duerden ◽  
S M Bartlett ◽  
G F Gibbons
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Inhibitory Effect ◽  
Diabetic Rats ◽  
Whole Body ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Short Period ◽  
Streptozotocin Diabetic Rats ◽  
Cholesterol Secretion

Hepatocytes were derived from 2-3-day streptozotocin-diabetic rats and maintained in culture for up to 3 days. Compared with similar cultures from normal animals, these hepatocytes secreted less very-low-density-lipoprotein (VLDL) triacylglycerol, but the decrease in the secretion of VLDL non-esterified and esterified cholesterol was not so pronounced. This resulted in the secretion of relatively cholesterol-rich VLDL particles by the diabetic hepatocytes. Addition of insulin for a relatively short period (24 h) further decreased the low rates of VLDL triacylglycerol secretion from the diabetic hepatocytes. The secretion of VLDL esterified and non-esterified cholesterol also declined. These changes occurred irrespective of whether or not exogenous fatty acids were present in the culture medium. Little or no inhibitory effect of insulin was observed after longer-term (24-48 h) exposure to the hormone. Both dexamethasone and a mixture of lipogenic precursors (lactate plus pyruvate) stimulated VLDL triacylglycerol and cholesterol secretion, but not to the levels observed in hepatocytes from normal animals. The low rate of hepatic VLDL secretion in diabetes contrasts with the increase in whole-body VLDL production rate. This suggests that the intestine is a major source of plasma VLDL in insulin-deficient diabetes.

scholarly journals PEMANFAATA N EKSTRAK DAUN WUNGU {Graptophyllum pictum (L.) Griff.} UNTUK PENURUNAN KADAR KOLESTEROL SERUM DARAH MENCIT BETINA YANG DIOVARIEKTOMI

2008 ◽  
Vol 13 (2) ◽  
pp. 97-100
Author(s):  
Listijani Suhargo
Keyword(s):  
High Density Lipoprotein ◽  
Fish Oil ◽  
Blood Serum ◽  
High Density Lipoprotein Cholesterol ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Low Density ◽  
Ovariectomized Mice

The purpose of this research was conducted to evaluate the effects of daun wungu extracts to decrease total cholesterol, LDL (Low Density Lipoprotein) and HDL (High Density Lipoprotein) cholesterol of ovariectomized mice. This research used 24 ovariectomized mice and 8 normal mice. The ovariectomized mice were grouped in 3 groups for K1 (the treatment with aquadest, 0.05 ml), K2 (the treatment with fish oil, 0.05 ml) and P (the treatment with daun wungu extracts, 0.5 mg in 0.05 ml fish oil). All treatments were done for 20 days. At the end of the treatments, the blood (0.5 ml) was taken from cardiac by tuberculin disposable syringe. And then with fotometry, serum total, LDL and HDL cholesterol were measured. The result of this research showed that daun wungu extracts (0.5 mg in 0.05 ml fish oil) could not decrease HDL cholesterol, but it could decrease total and LDL cholesterol of blood serum in ovariectomized mice.

scholarly journals The Hypoglycaemic, Antihyperlipidemic and Antioxidative Effects of Anacardium Occidentale Methanolic Nut Extract in Streptozotocin-Induced Diabetic Male Wistar Rats

2021 ◽  
Author(s):  
Folasade O. AJAO ◽  
Michael A. Olamoyegun ◽  
Marcus O. Iyedupe
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Wistar Rats ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Anacardium Occidentale ◽  
Low Density ◽  
Reference Drug ◽  
Antioxidative Effects ◽  
Group 2

Abstract Background: This research work investigated the antidiabetic, anti-hyperlipidemic, and antioxidative effects of Anacardium occidentale methanolic nut extract in Streptozotocin (STZ)-induced diabetic Wistar rats. Methods: Forty (40) Wistar rats weighing 250±30g were randomly divided into five groups of 8 rats each. Group 1 served as the control; Group 2-5 were induced with diabetes with a single dose of 50mg/kg bw of streptozotocin intraperitoneally. After diabetes induction, Group 2 served as the STZ-only group, Groups 3 and 4 were administered 100mg/kg bw and 200mg/kg bw p.o Anacardium occidentale nut extract, respectively, while Group 5 was administered 2mg/kg bw of glimepiride as a reference drug for a period of 4 weeks. Food and water intake were monitored daily, body weight, and blood glucose levels weekly throughout the experiment. On day 29, the animals were sacrificed, and blood samples were collected through cardiac puncture for biochemical studies. Results: Administration of the nut extract significantly (p<0.05) increased the food intake and body weight of diabetic treated rats, fasting blood glucose level and oral glucose tolerance test (OGTT) decreased significantly (p<0.05) in treated rats. On lipid profile, administration of nut extract significantly decreased (p<0.05) triglyceride, low-density lipoprotein, total cholesterol, and very-low-density lipoprotein concentrations while it significantly increases (p<0.05) the high-density lipoprotein. Anacardium occidentale nut extract caused significantly (p<0.05) increases in SOD, GPx, GSH, and CAT levels with a decrease MDA level in diabetic treated rats. Markers of liver and kidney functions were also improved in diabetic treated rats.Conclusion: Treatment with Anacardium occidentale methanolic nut extract has hypoglycemic, hypolipidemic, and hepato-protective effects in diabetic rats. It also alleviates oxidative stress activity and restoration of markers of kidney function, and may be useful as alternative therapy in the management of diabetes and its related complications.

Abstract 14430: Effect Modification of Statin Therapy on the Relationship of Low-density Lipoprotein Cholesterol With Incident CKD in Us Veterans

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Jui-Ting Hsiung ◽  
Maria Marroquin ◽  
Kamyar Kalantar-Zadeh
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Us Veterans ◽  
The Impact ◽  
Statin Use

Background: Studies suggests that in the general population, hyperlipidemia may confer higher risk of developing chronic kidney disease (CKD). But, there is conflicting data as to whether statins can protect renal function or slow renal degradation. We sought to examine the impact of statins on the association of low-density lipoprotein cholesterol (LDL) and risk of incident CKD. Methods: Our cohort included 1,439,756 US veterans without chronic kidney disease (CKD), but with LDL measured between 2004-2006, who were followed until 2014. Incident CKD was defined as over 3 estimated glomerular filtration rate (eGFR) measurements <60 mL/min/1.73m 2 at least 90 days apart. Patients with a statin prescription at the time of LDL measurement were identified. Cox models were used to estimate the associations between LDL with incident CKD. Model adjustments include demographics, comorbidities, smoking status, prescription of fibrate or niacin, body mass index, albumin, high-density lipoprotein cholesterol, and triglycerides. Results: The cohort included 5% females, 16% African Americans, 26% diabetics, and 30% statin-users, with a mean age of 60±13 years. The median [IQR] of LDL and eGFR were 109 [88,133] mg/dL and 83 [72,94] mL/min/1.73m 2 , respectively. A J-shaped association between LDL and incident CKD were observed in both those on statin and not on a statin after adjustment. Low LDL (<70 mg/dL) was associated with a higher risk of incident CKD compared to the reference (LDL 70-<100 mg/dL) regardless of statin use. High LDL ≥160 mg/dL was associated with the highest of risks of incident CKD (HR: 1.08, 95% CI: 1.04, 1.13, and HR: 1.10, 95% CI: 1.07, 1.12, for statin use and no statin use, respectively). Conclusion: Both high and low LDL were associated with higher incident CKD risk independent of statin use in this US veteran cohort. Further studies are needed to understand how to manage cardiovascular disease risk by lowering LDL while simultaneously reducing risk of CKD.

scholarly journals Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events

2020 ◽  
Vol 9 (23) ◽  
Author(s):  
Peter Willeit ◽  
Calvin Yeang ◽  
Patrick M. Moriarty ◽  
Lena Tschiderer ◽  
Stephen A. Varvel ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Clinical Care ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cholesterol Content ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Lipoprotein A ◽  
The Impact

Background Conventional "low‐density lipoprotein cholesterol (LDL‐C)" assays measure cholesterol content in both low‐density lipoprotein and lipoprotein(a) particles. To clarify the consequences of this methodological limitation for clinical care, our study aimed to compare associations of “LDL‐C” and corrected LDL‐C with risk of cardiovascular disease and to assess the impact of this correction on the classification of patients into guideline‐recommended LDL‐C categories. Methods and Results Lipoprotein(a) cholesterol content was estimated as 30% of lipoprotein(a) mass and subtracted from “LDL‐C” to obtain corrected LDL‐C values (LDL‐C corr30 ). Hazard ratios for cardiovascular disease (defined as coronary heart disease, stroke, or coronary revascularization) were quantified by individual‐patient‐data meta‐analysis of 5 statin landmark trials from the Lipoprotein(a) Studies Collaboration (18 043 patients; 5390 events; 4.7 years median follow‐up). When comparing top versus bottom quartiles, the multivariable‐adjusted hazard ratio for cardiovascular disease was significant for “LDL‐C” (1.17; 95% CI, 1.05–1.31; P =0.005) but not for LDL‐C corr30 (1.07; 95% CI, 0.93–1.22; P =0.362). In a routine laboratory database involving 531 144 patients, reclassification of patients across guideline‐recommended LDL‐C categories when using LDL‐C corr30 was assessed. In “LDL‐C” categories of 70 to <100, 100 to <130, 130 to <190, and ≥190 mg/dL, significant proportions (95% CI) of participants were reassigned to lower LDL‐C categories when LDL‐C corr30 was used: 30.2% (30.0%–30.4%), 35.1% (34.9%–35.4%), 32.9% (32.6%–33.1%), and 41.1% (40.0%–42.2%), respectively. Conclusions “ LDL‐C” was associated with incident cardiovascular disease only when lipoprotein(a) cholesterol content was included in its measurement. Refinement in techniques to accurately measure LDL‐C, particularly in patients with elevated lipoprotein(a) levels, is warranted to assign risk to the responsible lipoproteins.

Sign in / Sign up

Export Citation Format

Share Document